|
Spectra Optia® Apheresis System
Photo: CaridianBCT |
|
LAKEWOOD, Colorado, USA - May 18, 2010
CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, today announced the protocol to perform
Red Blood Cell Exchange (RBCX) on the
Spectra Optia® Apheresis System is now available for use in
Canada.
Red Blood Cell Exchange procedures are prescribed to treat various hematologic, metabolic and infectious diseases, primarily those diseases in which defective or damaged red blood cells play a major role in the pathology.
|
|
|
Spectra Optia® Apheresis Product
Photo: CaridianBCT |
|
The RBCX protocol supplements the
Spectra Optia system's Therapeutic Plasma Exchange (TPE) protocol-enabling health care professionals to select the most appropriate, individualized procedures to optimize patient care.
"Delivering additional protocols on the Spectra Optia system contributes to its enhanced versatility, performance and patient care for our customers," said
Tom Jordan, senior vice president of Therapeutic Apheresis and Cell Therapy Systems at CaridianBCT.
"We are excited to launch the RBCX protocol in Canada, and are currently under FDA review for 510(k) clearance to release in the United States."
The RBCX protocol release in
Canada follows the November 2009 launch in
Europe, the
Middle East and
Africa (EMEA),
Australia and areas of
Asia.
Included in the family of protocols now available for the
Spectra Optia system are the
TPE protocol, available to
EMEA, Australia, the
United States and
Canada and the
Mononuclear Cell (MNC) protocol, launched in
EMEA and
Australia in October 2008.
About Spectra Optia Apheresis System
Based on
COBE® Spectra system technology, the
Spectra Optia system is a transportable therapeutic apheresis system that uses centrifugation for blood separation and a unique optical detection technology for interface management
(Automated Interface Management system).
|
Spectra Optia® Apheresis Product
Photo: CaridianBCT |
|
The Spectra Optia system, tubing sets, and software have received a
CE Mark and
510K clearance for the
TPE protocol, and a
CE Mark for the
MNC and
RBCX protocols.
About CaridianBCT
CaridianBCT is the leading global provider of innovative technologies and services specializing in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies.
The company serves patients through its commitment to better blood and better lives by developing and commercializing products that serve global customers in the blood banking, therapeutic apheresis and transfusion medicine industries.
For more information, visit
http://www.caridianbct.com/
Contact:
Tarra Ryerson, Manager of Global Corporate Communications
Mobile: +1 303.246.3868
press@caridianbct.com
http://www.caridianbct.com/location/north-america/about-caridianbct/press-room/Pages/18MAY,2010-CaridianBCT-Releases-Red-Blood-Cell-Exchange-Protocol-in-Canada.aspx
Spectra Optia® Apheresis System
The Spectra Optia Apheresis System, based on the COBE Spectra system, is the industry's next-generation therapeutic apheresis and cell therapy platform that allows operators to spend more time focusing on patient care.
The Spectra Optia system is:
• Streamlined to provide quality apheresis procedures
• Continuous flow centrifugation technology complete with an Automated Interface Management (AIM) system for patient safety, and procedural efficiency
• Intuitive and easy to use, simplifying operator training
• A single platform for customized procedures to satisfy unique customer and patient needs
|
Spectra Optia® Apheresis System
Photo: CaridianBCT |
|
Deliver versatility and performance:
• Multiple protocols on a single platform
• Tubing sets designed for multiple procedure types, minimizing training and reducing inventory and storage
Simplify operations:
• Convenient data management – Easy data storage and retrieval, with the ability to print or export information to address documentation requirements, reduce manual data transcription and improve data traceability
• Improved system mobility – A compact and stable design, including a collapsible monitor and IV pole, allows operators to easily move and store the system
Spend more time with patients, less time with technology:
• Focus on patient comfort and safety – Optimized fluid balance, customized anticoagulant infusion management and low extracorporeal volume tubing set
• Automated Interface Management – Perform real-time interface monitoring, interpretation and adjustment for flexible procedural control
• Intuitive touch screen and Graphical User Interface display – Access procedure data quickly and easily with fewer manual calculations
• Efficient screen navigation – Retrieve data for the right information, at the right time, in the right place
|
Spectra Optia® Apheresis System
Photo: CaridianBCT |
|
The Spectra Optia Apheresis System is a transportable therapeutic apheresis system that uses continuous flow centrifugation and optical detection technology
(Automated Interface Management or AIM system).
This advanced system offers operator choice and precision, and enables operators to perform a wide variety of procedures on one platform.
|
Spectra Optia® Apheresis System
Photo: CaridianBCT |
|
Intuitive Graphical User Interface (GUI):
• Simplifies screen navigation by presenting important procedural information all at once, at the right time
• Provides simple data entry, enabling operator to enter data directly without manual calculations
Convenient data management:
• Easily store and retrieve data
• Quickly view information in the reports screen
• Print or export procedure data to a computer
Automated Interface Management (AIM):
• Performs real-time interface monitoring, interpretation and adjustment while retaining operator control capabilities
• Monitors the interface position and thickness of separated blood components
• Interprets interface information using unique optical detection software
• Adjusts the pumps and valves to manage the interface position and efficiently remove targeted components
Tubing set versatility
Ability to perform multiple procedures on one tubing set type that:
• Minimizes operator training, errors and handling
• Reduces inventory cost and storage space
• Offers low tubing set volume and low total blood volume (TBV) applications
http://www.caridianbct.com/location/north-america/products-and-services/Pages/spectra-optia-apheresis-system.aspx
Apheresis Collections
At
CaridianBCT, the art of blood collections begins by providing blood centers with the flexibility and advanced technology needed to safely collect more of the specific components patients require, thus ensuring our customers have the right product, at the right time and in the right place to positively impact patients' lives.
|
Apheresis Collections
Photo: CaridianBCT |
|
Designed to optimize donations by collecting flexible combinations of blood components, the
Trima Accel® Automated Blood Collection System simplifies the process of delivering the lifesaving gift of blood:
• Collect any blood component, in any combination
• Target specific blood types
• Respond quickly to fluctuations in demand
|
Superior patient care through advanced technology, operator choice and precision.
Photo: CaridianBCT |
|
For an inclusive package, blood centers combine the
Trima Accel system with one of
CaridianBCT's powerful information systems to provide:
• Collection and procedural flexibility
• Capability to centrally manage and change priorities
http://www.caridianbct.com/location/north-america/our-markets/Pages/apheresis-collections.aspx
Our Culture
CaridianBCT's strong culture is maintained through teamwork, collaboration and creative approaches to new ideas and problem-solving.
Employees are encouraged to practice innovative thinking, engage in lifelong learning and, above all, relentlessly pursue quality in all that we do.
This operational framework rewards results, relationships, cross-functionality and individual accountability.
|
CaridianBCT Values
Photo: CaridianBCT |
|
As a company dedicated to the health and well-being of the global community, we support a vision,
For Better Blood and Better Lives.
We carry out this vision with values that provide the structure for our business practices and day-to-day actions.
Recognizing our geographically and culturally diverse staff,
CaridianBCT continuously seeks ways to help our people identify connections with colleagues and build relationships, creating bonds that empower us to influence others and get results both in and out of the office.
With a shared determination, collective wisdom and common goals,
CaridianBCT has long attracted and retained the best and brightest employees.
http://www.caridianbct.com/location/north-america/contact-us/Pages/our-culture.aspx
Tom Jordan
Senior Vice President and General Manager, Therapeutic Systems at CaridianBCT
|
Tom Jordan
Photo: CaridianBCT |
|
As senior vice president and general manager, Tom Jordan has worldwide responsibility for the strategic direction and successful execution of the Therapeutic Apheresis and Cell Therapy Systems business area.
In this role, his responsibilities include planning, sales, marketing, business development, regulatory, medical liaison programs and multiple product development platforms for therapeutic apheresis, cell therapy and cell expansion technologies.
In addition, Jordan serves as a leader overseeing all operations in the Asia Pacific region.
Jordan has extensive experience in the health care industry, particularly in therapeutic application areas within medical devices, pharmaceutical, molecular diagnostics and international markets.
Prior to joining CaridianBCT, Jordan served as chief commercial operations officer at Clinical Micro Sensors Inc., a wholly owned subsidiary of Motorola.
He also has held leadership positions at Baxter International Inc. and Global Healthcare Exchange LLC.
Jordan received his bachelor's degree in business administration with a concentration in finance studies from the University of Iowa.
Jordan holds dual citizenship in Germany and the United States.
David Perez
President and Chief Executive Officer of CaridianBCT
|
David Perez
Photo: CaridianBCT |
|
David Perez is president and chief executive officer of CaridianBCT, with more than two decades of leadership, management, commercial development, finance and operations experience in complex medical device and health care service businesses.
In this role, he guides the strategic direction, growth and execution of the global company and its mission to improve lives through innovation, quality and services delivered by the company's people, products and processes.
Currently, Perez is vice chair of the board of trustees for the National Blood Foundation (NBF), also serving on the NBF Council on Research and Development; a board member of the Foundation for America's Blood Centers®, and the Colorado BioScience Association; and on the board of directors at the Advanced Medical Technology Association (AdvaMed), as well as the chair of the Blood Products and Technology Sector for AdvaMed.
Prior to joining CaridianBCT in 1999, Perez held leadership positions at UroTherapies Inc., Haemonetics® Corp., Caremark LLC, Coram Healthcare Corp. and Kendall.
He earned his bachelor's degree in political science from Texas Tech University.
http://www.caridianbct.com/location/north-america/about-caridianbct/Pages/executive-leadership.aspx